ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
45 & Considering TRT: PCa Fam History: Rate My Labs
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 206685" data-attributes="member: 13851"><p><strong>Canadian Urological Association guideline on testosterone deficiency in men: Evidence-based Q&A (2021)</strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>Treatment risks</strong></p><p><strong></strong></p><p><strong>21. Does testosterone replacement therapy increase the risk of prostate cancer?</strong></p><p></p><p><em><strong>Despite historical teachings about the relationship between testosterone on prostate cancer biology and risk, there is now <u>consistent evidence that testosterone therapy does not increase a man’s risk for developing prostate cancer</u>.</strong> In the largest randomized controlled trial (RCT) to date (The Testosterone Trials), involving 790 men 65 years and older treated for 12 months with either testosterone gel or placebo, despite close surveillance, only one man developed prostate cancer during the course of the study.29 Supporting such observations, a meta-analysis of 22 RCTs involving 2351 men revealed no greater risk of developing prostate cancer among those who received testosterone therapy compared with those who received a placebo.53 There is no association between the risk of prostate cancer and serum testosterone concentrations. Men with the highest naturally occurring (endogenous) testosterone levels do not exhibit significantly higher prostate-specific antigen (PSA) levels or a greater subsequent risk of developing prostate cancer than men with the lowest levels of endogenous testosterone.54,55 <strong>Finally, the evolving literature suggests that among appropriately selected hypogonadal men with prostate cancer managed with active surveillance, radical prostatectomy, or radiation therapy, testosterone therapy does not appear to significantly increase the risk of biochemical (PSA) progression, local or metastatic progression, overall mortality, and cancer-specific mortality.56-58</strong></em></p><p><em><strong></strong></em></p><p><em><strong>Symptomatic men with TD who have been diagnosed with localized prostate cancer and treated (surgery, radiation) or followed with active surveillance without evidence of active disease can be considered for a medically supervised trial of testosterone therapy (low LE, weak recommendation). Consultation with a urologist is recommended. Patients with metastatic or high-risk prostate cancer who are likely to require androgen deprivation therapy should not be offered testosterone therapy (moderate LE, strong recommendation).5</strong></em></p><p><em></em></p></blockquote><p></p>
[QUOTE="madman, post: 206685, member: 13851"] [B]Canadian Urological Association guideline on testosterone deficiency in men: Evidence-based Q&A (2021) Treatment risks 21. Does testosterone replacement therapy increase the risk of prostate cancer?[/B] [I][B]Despite historical teachings about the relationship between testosterone on prostate cancer biology and risk, there is now [U]consistent evidence that testosterone therapy does not increase a man’s risk for developing prostate cancer[/U].[/B] In the largest randomized controlled trial (RCT) to date (The Testosterone Trials), involving 790 men 65 years and older treated for 12 months with either testosterone gel or placebo, despite close surveillance, only one man developed prostate cancer during the course of the study.29 Supporting such observations, a meta-analysis of 22 RCTs involving 2351 men revealed no greater risk of developing prostate cancer among those who received testosterone therapy compared with those who received a placebo.53 There is no association between the risk of prostate cancer and serum testosterone concentrations. Men with the highest naturally occurring (endogenous) testosterone levels do not exhibit significantly higher prostate-specific antigen (PSA) levels or a greater subsequent risk of developing prostate cancer than men with the lowest levels of endogenous testosterone.54,55 [B]Finally, the evolving literature suggests that among appropriately selected hypogonadal men with prostate cancer managed with active surveillance, radical prostatectomy, or radiation therapy, testosterone therapy does not appear to significantly increase the risk of biochemical (PSA) progression, local or metastatic progression, overall mortality, and cancer-specific mortality.56-58 Symptomatic men with TD who have been diagnosed with localized prostate cancer and treated (surgery, radiation) or followed with active surveillance without evidence of active disease can be considered for a medically supervised trial of testosterone therapy (low LE, weak recommendation). Consultation with a urologist is recommended. Patients with metastatic or high-risk prostate cancer who are likely to require androgen deprivation therapy should not be offered testosterone therapy (moderate LE, strong recommendation).5[/B] [/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
45 & Considering TRT: PCa Fam History: Rate My Labs
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top